JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice TargetHot
JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $900 to $950.
JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $900 to $950.